APA (7th ed.) Citation

Fanale, M. A., Forero-Torres, A., Rosenblatt, J. D., Advani, R. H., Franklin, A. R., Kennedy, D. A., . . . Bartlett, N. L. (2012). A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clinical cancer research, 18(1), 248. https://doi.org/10.1158/1078-0432.CCR-11-1425

Chicago Style (17th ed.) Citation

Fanale, Michelle A., Andres Forero-Torres, Joseph D. Rosenblatt, Ranjana H. Advani, Anna R. Franklin, Dana A. Kennedy, Tae H. Han, Eric L. Sievers, and Nancy L. Bartlett. "A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/refractory CD30-positive Hematologic Malignancies." Clinical Cancer Research 18, no. 1 (2012): 248. https://doi.org/10.1158/1078-0432.CCR-11-1425.

MLA (9th ed.) Citation

Fanale, Michelle A., et al. "A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/refractory CD30-positive Hematologic Malignancies." Clinical Cancer Research, vol. 18, no. 1, 2012, p. 248, https://doi.org/10.1158/1078-0432.CCR-11-1425.